Vyriad Secures $25M Series B Funding Led by Stine Seed Farms

Why It Matters

The infusion of $85 million accelerates a novel viral CAR‑T platform, potentially reshaping treatment options for aggressive multiple myeloma and validating the commercial appeal of in vivo gene‑editing therapies.

Key Takeaways

• $25M tranche brings Series B total to $85M.
• Funds enable first‑in‑human trial of VV169.
• Lead investor Harry Stine, seed industry magnate.
• Partnerships include Regeneron and Novartis.
• Vyriad targets in vivo CAR‑T via engineered viruses.

Pulse Analysis

The biotech sector has seen a surge in financing for next‑generation gene‑editing platforms, and Vyriad’s $85 million Series B underscores investor confidence in viral vector technologies. By combining oncolytic virotherapy with in vivo CAR‑T engineering, Vyriad aims to bypass the logistical complexities of ex vivo cell manufacturing, offering a potentially more scalable and cost‑effective cancer treatment. This financing round not only fuels the imminent Phase 1 trial of VV169 but also positions the company to expand its pipeline of viral‑based therapeutics across solid and hematologic malignancies.

Multiple myeloma remains a therapeutic frontier, with patients relapsing after standard regimens. VV169’s design—delivering a CAR construct directly to malignant plasma cells—promises rapid immune activation without the need for patient‑specific cell processing. Early clinical data could set a new benchmark for in vivo CAR‑T efficacy and safety, influencing both regulatory pathways and competitive dynamics among biotech firms pursuing similar approaches. Vyriad’s collaboration with Regeneron and Novartis further enhances its scientific credibility and may accelerate downstream development milestones.

From an investment perspective, the involvement of Harry Stine, a leader in agricultural genetics, signals a cross‑industry recognition of viral platforms’ transformative potential. Family office participation reflects a growing appetite for high‑risk, high‑reward oncology ventures. As Vyriad moves toward patient enrollment, the market will closely watch trial outcomes, which could unlock additional capital, strategic partnerships, and eventual commercial rollout, reshaping the landscape of targeted genetic medicines.

Deal Summary

Biotech firm Vyriad announced the closing of a $25 million final tranche of its Series B financing, bringing the total round to $85 million. The round was led by Harry Stine of Stine Seed Farms, with participation from family offices. The funding will support first‑in‑human testing of its in vivo CAR‑T candidate VV169 for multiple myeloma.